Side-by-side · Research reference
MOTS-cvsThymalin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongReviewed16/68 cited
BHuman-MechanisticDraft12/40 cited
MOTS-c
Mitokine · Mitochondria-Encoded
SQ · Variable · 2–3×/week
Thymalin
Immune restorer · Russian peptide bioregulator
IM · Daily for 5–10 days · 1-2×/year
01Mechanism of Action
Parameter
MOTS-c
Thymalin
Primary target
Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015
T-cell precursors + thymus-axis maturation pathwayKhavinson 2002
Pathway
Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002
Downstream effect
Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015
Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002
Origin
Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021
Polypeptide fraction isolated from calf thymus extractKhavinson 2002
Antibody development
—
—
02Dosage Protocols
Parameter
MOTS-c
Thymalin
Standard dose
5–10 mg / weekLee 2015
Experimental, extrapolated from animal data. No human RCT-derived dose.
5–10 mg / day IM × 5–10 daysKhavinson 2002
Frequency
2–3× per week
Short half-life may necessitate more frequent dosing for saturation.
Once daily during cycle
Lower / starter dose
2.5–5 mg / week
Recommended due to limited human data.
2.5 mg / day
Evidence basis
Animal + anecdotalLee 2015Reynolds 2021A first-in-human phase 1 study 2021
Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.
Russian clinical + in vitroKhavinson 2002
Duration
4–12 weeks (experimental)
Optimal cycle length unknown.
5–10 day cycles, 1–2× per year
Reconstitution
Bacteriostatic water, 1–2 mL
10 mg/mL at 1 mL.
Saline or bacteriostatic water
Timing
Pre-workout or fasted state preferred
Activity-context amplifies AMPK response.
Morning preferred
Half-life
Minutes to hours (estimated)
Systemically unstable; native MOTS-c PK in humans not fully characterised.
Hours (estimated)
03Metabolic / Fat Loss Evidence
Parameter
MOTS-c
Thymalin
Primary fat target
Diet-induced / metabolic obesity; systemic fat utilization
—
Quantified reduction
Significant HFD fat gain ↓Lee 2015
Murine models, dose-dependent (5 & 15 mg/kg).
—
IGF-1 impact
No direct IGF-1 pathway; AMPK-mediated
—
Effect on lean mass
High dose significantly ↑ lean mass in mice
—
Triglycerides
AMPK-driven FA oxidation suggests TG benefit (not directly measured)
—
Effect reversibility
Unknown — no long-term follow-up data
—
Key publication
Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015Reynolds 2021Kim 2018
—
04Side Effects & Safety
Parameter
MOTS-c
Thymalin
Injection site reaction
Mild irritation (reported)
Mild erythema at IM site
Fluid retention / Edema
Not reported
—
Cardiovascular
Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats
—
Cancer risk
Contradictory data — some models suggest pro-proliferative effects
—
CNS / Neurological
Insomnia, headache (anecdotal reports)
—
GI symptoms
Nausea, stomach discomfort (reported)
—
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
Avoid
Evidence quality
Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021
—
Allergic reaction
—
Rare hypersensitivity to bovine-derived polypeptide
Autoimmune flare
—
Theoretical risk in active autoimmune disease
Long-term safety
—
Limited Western data
Absolute Contraindications
MOTS-c
- ·Pregnancy / breastfeeding (insufficient data)
Thymalin
- ·Pregnancy / breastfeeding
- ·Bovine protein hypersensitivity
Relative Contraindications
MOTS-c
- ·Active cancer or cancer predisposition
- ·AMPK pathway deficiency (efficacy nullified)
- ·Use with cancer-promoting medications (theoretical)
Thymalin
- ·Active autoimmune disease
- ·Concurrent immunosuppressant therapy
05Administration Protocol
Parameter
MOTS-c
Thymalin
1. Reconstitution
Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.
Add 1–2 mL saline or bacteriostatic water per 10 mg vial.
2. Injection site
Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.
Intramuscular — deltoid or gluteal. Rotate sites.
3. Timing
Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.
Morning preferred during cycle.
4. Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.
Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.
5. Needle
27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.
23–25G, 25–38 mm IM needle.
06Stack Synergy
MOTS-c
+ Ipamorelin
ModerateMOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.
- MOTS-c
- 5 mg SQ · pre-workout (2–3×/wk)
- Ipamorelin
- 200–300 mcg SQ · pre-sleep (daily)
- Primary benefit
- Metabolic flexibility + GH recovery + ROS reduction
Thymalin
+ Thymosin α-1
ModerateThymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.
- Thymalin
- 5–10 mg IM · daily × 7 days
- Thymosin α-1
- 1.6 mg SQ · 2× weekly during the cycle
- Primary benefit
- Broad thymic restoration + targeted immune activation